Cargando…
Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
Recent advances in cancer immunotherapy have completely revolutionized cancer treatment strategies. Nonetheless, the increasing incidence of immune-related adverse events (irAEs) is now limiting the overall benefits of these treatments. irAEs are well-recognized side effects of some of the most effe...
Autores principales: | Bayless, Nicholas L, Bluestone, Jeffrey A, Bucktrout, Samantha, Butterfield, Lisa H, Jaffee, Elizabeth M, Koch, Christian A, Roep, Bart O, Sharpe, Arlene H, Murphy, William J, Villani, Alexandra-Chloé, Walunas, Theresa L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420733/ https://www.ncbi.nlm.nih.gov/pubmed/34479924 http://dx.doi.org/10.1136/jitc-2021-002627 |
Ejemplares similares
-
Preamble to the 2015 SITC immunotherapy biomarkers taskforce
por: Butterfield, Lisa H, et al.
Publicado: (2015) -
Concise AACR2
por: Gorman, Michael E
Publicado: (1989) -
ICM-AACR-INC
Publicado: (2009) -
The Concise AACR2
por: Gorman, Michael
Publicado: (2004) -
Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016
por: Gulley, James L., et al.
Publicado: (2017)